- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
BRCA: A Primary Care Concern?
October is Ovarian Cancer Awareness Month. Find out in this podcast with Harvard professor Richard Penson, MD, what traits in your female patients should prompt testing.
©Gts/Shutterstock.com
Which of your patients is at risk for BRCA-mutated ovarian cancer? When should you recommend testing?
Dr. Richard Penson, Associate Professor of Medicine at Harvard Medical School, and one of the Clinical Directors at Massachusetts General Hospital in Boston addresses these and other questions related to ovarian cancer and primary care in this podcast:
- What is the relevance of BRCA gene mutation to primary care?
- How common is this mutation in the US?
- How does a BRCA gene mutation affect ovarian cancer diagnosis and treatment?
- What are the options for patients who test positive for the BRCA mutation?
Dr. Richard Penson is Associate Professor of Medicine at Harvard Medical School. Dr. Penson came from St Bartholomew's Hospital, London, in 1997 and his practice is devoted almost exclusively to gynecologic oncology with the majority of patients having ovarian cancer. Dr. Penson sits on the national Gynecologic Oncology Group (GOG) committees for quality of life research, and the NCCN Ovarian Committee. Dr. Penson attends on the Bigelow General Medical Service at Mass General, serves as the chairman for panels C, and F of the Institutional Review Board of Dana-Farber/Partners CancerCare.
